Scarica l'app Stockscreener
16.04
3.22%
0.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ADPT Giù?
Forum
Previsione
Precedente Chiudi:
$15.54
Aprire:
$15.53
Volume 24 ore:
1.34M
Relative Volume:
0.57
Capitalizzazione di mercato:
$2.47B
Reddito:
$205.22M
Utile/perdita netta:
$-121.24M
Rapporto P/E:
-19.70
EPS:
-0.8141
Flusso di cassa netto:
$-82.81M
1 W Prestazione:
+1.71%
1M Prestazione:
-11.23%
6M Prestazione:
+23.38%
1 anno Prestazione:
+88.26%
Intervallo 1D:
$15.42
$16.42
Intervallo di 1 settimana:
$14.85
$16.42
Portata 52W:
$6.255
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Nome
Adaptive Biotechnologies Corp
Settore
Industria
Telefono
206-659-0067
Indirizzo
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
16.04 | 2.39B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Iniziato | Guggenheim | Buy |
| 2025-06-18 | Iniziato | Craig Hallum | Buy |
| 2025-03-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-12-21 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Underperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Reiterato | BTIG Research | Buy |
| 2022-02-16 | Reiterato | BofA Securities | Buy |
| 2022-02-16 | Reiterato | Goldman | Neutral |
| 2022-02-16 | Reiterato | JP Morgan | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-03-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Iniziato | Goldman | Buy |
| 2019-07-23 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | BofA/Merrill | Buy |
| 2019-07-22 | Iniziato | Cowen | Outperform |
| 2019-07-22 | Iniziato | Goldman | Neutral |
| 2019-07-22 | Iniziato | Guggenheim | Buy |
| 2019-07-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Adaptive Biotechnologies Corp Borsa (ADPT) Ultime notizie
Principal Financial Group Inc. Sells 303,285 Shares of Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Buy Signal: What is the earnings history of EUDAW2025 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Allianz Asset Management GmbH Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells 2,145 Shares of Stock - MarketBeat
ADPT: BTIG Raises Price Target Following Analyst Update | ADPT S - GuruFocus
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $21.00 - MarketBeat
ADPT: JP Morgan Raises Price Target and Maintains Overweight Rat - GuruFocus
Adaptive Biotechnologies (ADPT) stock swings after earnings as MRD guidance, insider sale draw scrutiny - TechStock²
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth - Investing.com UK
Adaptive Biotechnologies Corp (ADPT) Q4 2025 Earnings Call Highl - GuruFocus
Adaptive Biotech (ADPT) Earnings Call Transcript - The Globe and Mail
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Adaptive Biotechnologies Q4 2025 slides: 55% revenue growth as MRD business expands - Investing.com
Adaptive Biotechnologies (ADPT) Sees Strong Revenue Growth and P - GuruFocus
Earnings call transcript: Adaptive Biotechnologies beats Q4 2025 expectations - Investing.com
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Adaptive Biotechnologies soars after beating Q4 expectations By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies soars after beating Q4 expectations - Investing.com
Adaptive Biotechnologies: Fourth Quarter Financial Highlights - Bitget
Adaptive Biotechnologies: Q4 Earnings Snapshot - king5.com
Adaptive Biotechnologies earnings beat by $0.09, revenue topped estimates - Investing.com
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Biotech Adaptive Biotechnologies lifts 2025 revenue 55%, narrows loss - Stock Titan
Adaptive Biotechnologies earnings on deck: Path to profitability in focus By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies earnings on deck: Path to profitability in focus - Investing.com
Adaptive Biotechnologies CEO Robins sells $2.3 million in stock - Investing.com
Adaptive Biotechnologies CEO Robins sells $2.3 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock - Investing.com
Harlan Robins Sells 8,120 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock - MarketBeat
Insider Sell: Harlan Robins Sells 42,788 Shares of Adaptive Biot - GuruFocus
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies Cor - GuruFocus
Adaptive Biotechnologies Executives Sell Shares - TradingView
299,180 Shares in Adaptive Biotechnologies Corporation $ADPT Acquired by Lisanti Capital Growth LLC - MarketBeat
Adaptive Biotechnologies Reports Strong Revenue Growth Amid Strategic Shift - AD HOC NEWS
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences - The Manila Times
Biotech using immune genetics schedules Feb. and March investor webcasts - stocktitan.net
The Analyst Verdict: Adaptive Biotechnologies In The Eyes Of 4 Experts - Benzinga
Guggenheim Raises Price Target for ADPT to $21, Maintains Buy Ra - GuruFocus
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 - The Manila Times
First Week of March 20th Options Trading For Adaptive Biotechnologies (ADPT) - Nasdaq
Sumitomo Mitsui Trust Group Inc. Trims Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Aug Selloffs: Will Adaptive Biotechnologies Corporation stock go up in YEARJuly 2025 Spike Watch & Comprehensive Market Scan Insights - baoquankhu1.vn
Adaptive Biotechnologies Insider Sold Shares Worth $1,411,131, According to a Recent SEC Filing - marketscreener.com
Adaptive Biotechnologies Corp Azioni (ADPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adaptive Biotechnologies Corp Azioni (ADPT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PISKEL KYLE | Chief Financial Officer |
Feb 04 '26 |
Sale |
18.46 |
2,145 |
39,597 |
216,637 |
| ROBINS HARLAN S | Chief Scientific Officer |
Feb 02 '26 |
Sale |
18.60 |
34,668 |
644,825 |
1,187,644 |
| ROBINS HARLAN S | Chief Scientific Officer |
Feb 03 '26 |
Sale |
19.00 |
8,120 |
154,280 |
1,179,524 |
| ROBINS CHAD M | CEO and Chairman |
Feb 02 '26 |
Sale |
18.44 |
124,998 |
2,304,963 |
2,459,245 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):